Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ALLO

Allogene Therapeutics Inc

Apr 19 • 04:00PM ET

3.47

Dollar change +0.01
Percentage change 0.29	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF VB VBK IWN IBB LABU SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-2.09	Insider Own	38.07%	Shs Outstand	169.09M	Perf Week	-8.68%
Market Cap	586.74M	Forward P/E	-	EPS next Y	-1.55	Insider Trans	-0.03%	Shs Float	104.72M	Perf Month	-21.67%
Income	-323.79M	PEG	-	EPS next Q	-0.41	Inst Own	60.84%	Short Float	29.24%	Perf Quarter	12.30%
Sales	0.16M	P/S	3667.14	EPS this Y	21.14%	Inst Trans	5.07%	Short Ratio	13.08	Perf Half Y	12.66%
Book/sh	3.47	P/B	1.00	EPS next Y	5.90%	ROA	-	Short Interest	30.62M	Perf Year	-29.61%
Cash/sh	2.65	P/C	1.31	EPS next 5Y	1.00%	ROE	-	52W Range	2.23 - 6.89	Perf YTD	8.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.18%	ROI	-48.10%	52W High	-49.64%	Beta	0.86
Dividend TTM	-	Quick Ratio	12.58	Sales past 5Y	-27.79%	Gross Margin	-7505.91%	52W Low	55.61%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	12.58	EPS Y/Y TTM	10.07%	Oper. Margin	-196516.88%	RSI (14)	30.00	Volatility	5.29% 5.78%
Employees	-	Debt/Eq	0.19	Sales Y/Y TTM	-24.70%	Profit Margin	-202366.25%	Recom	1.69	Target Price	12.08
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	22.55%	Payout	-	Rel Volume	0.86	Prev Close	3.46
Sales Surprise	-4.55%	EPS Surprise	-13.13%	Sales Q/Q	-55.32%	Earnings	Mar 14 AMC	Avg Volume	2.34M	Price	3.47
SMA20	-13.89%	SMA50	-22.82%	SMA200	-8.54%	Trades		Volume	2,013,218	Change	0.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Stifel	Buy → Hold	$44 → $18
Oct-08-21	Downgrade	Goldman	Buy → Neutral	$71 → $20
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy	$53
May-20-21	Upgrade	Truist	Hold → Buy	$34 → $41
May-14-21	Initiated	B. Riley Securities	Buy	$52

Show Previous Ratings

Apr-11-24 02:45PM	3 Meme Stocks to Sell and Replace With Meme Coins (InvestorPlace)
Apr-09-24 08:30AM	Allogene Therapeutics Announces Q2 Investor Conference Participation (GlobeNewswire)
Apr-08-24 08:46AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Mar-16-24 04:35PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 09:32AM	Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss (Zacks)
07:04AM	Loading…
07:04AM	Q4 2023 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 08:55PM	ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.89%
05:34PM	Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ... (GuruFocus.com)
05:15PM	Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update (GlobeNewswire)
Mar-13-24 12:15PM	Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology (Zacks)
Mar-12-24 08:50AM	Allogene taps Arbor in pursuit of off-the-shelf CAR-T therapies for autoimmune disease (BioPharma Dive)
08:30AM	Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease (GlobeNewswire)
Mar-05-24 09:55AM	Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
08:30AM	Loading…
08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update (GlobeNewswire)
Feb-28-24 08:30AM	Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-16-24 08:30AM	Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia (GlobeNewswire)
Jan-16-24 04:05PM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-12-24 08:34AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Jan-05-24 12:52PM	Allogene (ALLO) Down 20% on Strategic Changes in Pipeline (Zacks) -14.01%
08:25AM	UPDATE 2-Allogene to cut 22% of its workforce (Reuters)
08:13AM	Allogene to cut 22% of its workforce (Reuters)
Jan-04-24 04:15PM	Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (GlobeNewswire)
04:05PM	Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (GlobeNewswire)
11:05AM	Allogene to shift strategy in bid to reposition CAR-T (BioPharma Dive)
Jan-03-24 04:05PM	Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.01%
Dec-09-23 12:00PM	Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology (GlobeNewswire)
Dec-01-23 08:30AM	Allogene Therapeutics Announces Participation in December Investor Conference (GlobeNewswire) +7.23%
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
12:00PM	Loading…
Nov-10-23 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-03-23 12:15PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript (Insider Monkey) +17.85%
12:00PM	Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak and Dagger Technologies at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
12:00PM	Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
10:15AM	Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-02-23 07:33PM	Allogene Therapeutics Inc (ALLO) Reports Q3 2023 Financial Results (GuruFocus.com)
04:12PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
09:00AM	Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology (GlobeNewswire)
Oct-30-23 08:30AM	Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +9.09%
Oct-26-23 08:30AM	Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-16-23 09:26AM	The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics (Zacks)
08:30AM	Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer (GlobeNewswire)
Sep-27-23 09:09AM	Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-25-23 08:45AM	JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment (Investing.com)
Sep-05-23 08:30AM	Allogene Therapeutics Announces Participation in September Investor Conference (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
Aug-17-23 08:44AM	11 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Aug-14-23 08:30AM	Allogene Therapeutics Appoints Earl Douglas as General Counsel (GlobeNewswire)
Aug-03-23 11:20AM	Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss (Zacks) +9.59%
Aug-02-23 05:25PM	Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Allogene Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:02PM	Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
10:41AM	Too Cheap to Ignore: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money (TipRanks)
Jul-26-23 08:30AM	Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jun-15-23 09:30AM	Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
Jun-14-23 08:00AM	Allogene Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire) -12.54%
Jun-09-23 06:25PM	Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
08:02AM	12 Best Short Squeeze Stocks to Buy Now (Insider Monkey)
Jun-03-23 09:00AM	Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-02-23 11:31AM	Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound? (Zacks) +5.45%
May-31-23 12:02PM	Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal (Zacks)
10:46AM	J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH (Zacks)
May-29-23 07:48AM	AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal (Zacks)
May-26-23 10:51AM	Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails (Zacks)
09:55AM	Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High? (Zacks)
08:23AM	PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study (Zacks)
May-25-23 03:16PM	Immutep (IMMP) Up on Initial Data From Lung Cancer Study (Zacks)
May-24-23 11:37AM	Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data (Zacks) -5.95%
08:30AM	Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
08:14AM	INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up (Zacks)
May-22-23 08:16AM	We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-19-23 11:16AM	PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study (Zacks)
10:24AM	AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease (Zacks)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace)
12:45PM	MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study (Zacks)
11:15AM	Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing (Zacks)
May-17-23 02:19PM	Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag (Zacks)
11:21AM	PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up (Zacks)
11:13AM	Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag (Zacks)
May-16-23 09:31AM	Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases (Zacks) -9.05%
May-12-23 12:08PM	ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why (Zacks)
11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
10:04AM	Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why (Zacks)
May-11-23 12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
11:50AM	Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress (GlobeNewswire)
09:44AM	Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates (Zacks)
09:33AM	TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines (Zacks)
07:44AM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow (Zacks)
May-10-23 09:55AM	Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 184.59%: Read This Before Placing a Bet (Zacks)
May-09-23 10:40AM	Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates (Zacks)
May-08-23 10:04AM	Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises (Zacks)
May-05-23 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update (Zacks)
May-04-23 03:29PM	Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance (Zacks) +12.76%
12:04PM	Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y (Zacks)
11:43AM	Q1 2023 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:43AM	Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss (Zacks)
May-03-23 05:25PM	Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +6.92%

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Jan 30 '24	Buy	3.60	190	683	819,590	Mar 06 09:52 PM
MESSEMER DEBORAH M.	Director	Dec 18 '23	Sale	2.70	18,640	50,317	62,456	Dec 20 04:26 PM
Mayo Stephen	Director	Aug 07 '23	Sale	4.29	10,000	42,855	25,328	Aug 09 04:07 PM

Open in Screener

ADAP

Adaptimmune Therapeutics Plc ADR

Apr 19 • 04:00PM ET

0.9767

Dollar change +0.0783
Percentage change 8.72	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ADAP Adaptimmune Therapeutics Plc ADR daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-0.52	Insider Own	11.90%	Shs Outstand	227.17M	Perf Week	-15.80%
Market Cap	221.88M	Forward P/E	-	EPS next Y	-0.59	Insider Trans	-0.61%	Shs Float	200.15M	Perf Month	-26.56%
Income	-114.08M	PEG	-	EPS next Q	-0.15	Inst Own	62.38%	Short Float	1.60%	Perf Quarter	39.01%
Sales	60.69M	P/S	3.66	EPS this Y	-467.56%	Inst Trans	-0.50%	Short Ratio	1.61	Perf Half Y	66.45%
Book/sh	0.17	P/B	5.62	EPS next Y	-15.85%	ROA	-37.31%	Short Interest	3.20M	Perf Year	-35.32%
Cash/sh	0.65	P/C	1.51	EPS next 5Y	1.00%	ROE	-187.96%	52W Range	0.42 - 2.05	Perf YTD	23.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.30%	ROI	-192.17%	52W High	-52.36%	Beta	2.50
Dividend TTM	-	Quick Ratio	2.85	Sales past 5Y	134.88%	Gross Margin	83.77%	52W Low	132.55%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	2.85	EPS Y/Y TTM	48.98%	Oper. Margin	-250.53%	RSI (14)	32.27	Volatility	13.75% 9.64%
Employees	449	Debt/Eq	0.64	Sales Y/Y TTM	123.93%	Profit Margin	-187.98%	Recom	2.14	Target Price	3.50
Option/Short	Yes / Yes	LT Debt/Eq	0.50	EPS Q/Q	-18.55%	Payout	-	Rel Volume	0.74	Prev Close	0.90
Sales Surprise	-99.11%	EPS Surprise	75.76%	Sales Q/Q	-97.90%	Earnings	Mar 06 BMO	Avg Volume	1.99M	Price	0.98
SMA20	-25.68%	SMA50	-29.95%	SMA200	9.45%	Trades		Volume	1,476,276	Change	8.72%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-23	Initiated	Bryan Garnier	Buy	$3.60
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$5
Nov-09-22	Upgrade	Mizuho	Neutral → Buy	$9
May-28-21	Initiated	Barclays	Underweight	$4
Apr-22-20	Initiated	Mizuho	Neutral	$3
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12 → $5
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform	$16
Feb-25-16	Initiated	Citigroup	Buy	$15
Jun-01-15	Initiated	Leerink Partners	Outperform	$24
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Apr-15-24 02:12PM	Adaptimmune (ADAP) Down on End of Collaboration With Roche (Zacks) -9.48%
Apr-12-24 08:00AM	Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated (Newsfile) -10.08%
05:37AM	Roche, Adaptimmune part ways on cell therapy research (BioPharma Dive)
Mar-27-24 07:30PM	Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet (Newsfile)
Mar-07-24 01:42PM	Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:24AM	Loading…
08:24AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:52PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +17.12%
07:00AM	Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates (Newsfile)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-21-24 04:00PM	Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 (Newsfile) +19.05%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-13-24 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know (Zacks)
Jan-31-24 04:44PM	Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review (Newsfile) +9.74%
Jan-30-24 01:02PM	Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC (GuruFocus.com) +10.18%
Jan-16-24 11:17AM	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why (Zacks) -13.72%
07:37AM	Loading…
Jan-04-24 07:37AM	Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference (Newsfile) +12.40%
Dec-06-23 07:00AM	Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma (Newsfile)
Nov-30-23 10:52AM	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND (Zacks)
Nov-29-23 08:00AM	Adaptimmune Receives Transfer of IND for Lete-cel Program (Newsfile) +11.66%
Nov-13-23 09:35AM	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:35AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update (Newsfile) -5.57%
07:05AM	Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Newsfile)
Nov-07-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-31-23 08:00AM	Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS (Newsfile)
08:00AM	Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control (Newsfile)
Oct-27-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-25-23 08:06AM	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 (Newsfile)
Oct-23-23 04:15AM	Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO (Newsfile) +6.25%
Sep-11-23 08:00AM	Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development (Newsfile) +8.81%
07:29AM	Loading…
Aug-09-23 07:29AM	Adaptimmune Reports Second Quarter Financial Results and Business Update (Newsfile)
Aug-03-23 01:24PM	Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023 (Newsfile)
Jul-28-23 12:30PM	Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 07:28AM	Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even after 12% gain this past week (Simply Wall St.) -10.10%
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks)
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
Jun-23-23 09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
Jun-22-23 09:40AM	Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia (Zacks)
Jun-19-23 10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.33%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-09-23 10:52AM	Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review (Zacks)
Jun-06-23 06:50AM	Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study (Zacks)
Jun-05-23 11:40AM	Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros (Zacks)
10:22AM	Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study (Zacks)
Jun-01-23 03:29PM	Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company (Newsfile) +6.86%
May-30-23 09:35AM	Down -22.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Adaptimmune Therapeutics PLC (ADAP) (Zacks)
May-25-23 05:00PM	Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO (Newsfile)
May-12-23 07:29AM	Adaptimmune Reports First Quarter Financial Results and Business Update (Newsfile)
May-09-23 06:43AM	Is Adaptimmune Therapeutics (NASDAQ:ADAP) In A Good Position To Invest In Growth? (Simply Wall St.)
May-05-23 05:00AM	Zacks.com featured highlights Sweetgreen, Adaptimmune Therapeutics, Owl Rock Capital, MACOM Technology Solutions and Equity Commonwealth (Zacks)
Apr-28-23 12:00PM	Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023 (Newsfile)
Apr-18-23 11:49AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive But Perhaps Not Attractive Enough (Simply Wall St.)
Apr-12-23 10:42AM	Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK (Zacks)
Apr-11-23 12:13PM	Why Shares of Adaptimmune Therapeutics Jumped Tuesday (Motley Fool) +7.08%
08:00AM	Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune (Newsfile)
Mar-08-23 07:14AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:23AM	News Flash: Analysts Just Made A Huge Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts (Simply Wall St.)
Mar-06-23 01:08PM	Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company (Benzinga) -25.00%
06:30AM	Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update (Newsfile)
06:00AM	Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors (Newsfile)
Feb-22-23 08:00AM	Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023 (Newsfile)
Feb-16-23 08:00AM	Adaptimmune Announces Changes to Board of Directors (Newsfile)
Jan-09-23 08:00AM	Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma (Newsfile) -9.95%
Jan-08-23 07:06AM	Even after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five years (Simply Wall St.)
Dec-28-22 06:51AM	Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day (Zacks) -5.30%
Dec-27-22 09:05AM	3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying (Zacks)
Dec-23-22 01:20PM	Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma (Newsfile)
Dec-10-22 09:02AM	Hedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year losses (Simply Wall St.)
Nov-18-22 08:00AM	Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent (Newsfile)
Nov-13-22 07:28AM	New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP) (Simply Wall St.)
Nov-11-22 10:52AM	Lab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing (American City Business Journals) +13.06%
Nov-10-22 06:03AM	Adaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.) +5.71%
Nov-08-22 03:11PM	Why Adaptimmune Therapeutics Stock Is Glowing Green Today (Motley Fool) +25.30%
09:41AM	Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business (Simply Wall St.)
07:30AM	Adaptimmune Reports Third-Quarter Financial Results and Business Update (Newsfile)
07:00AM	Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers (Newsfile)
Oct-27-22 12:27PM	Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022 (Newsfile)
Oct-25-22 11:12AM	GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day (Benzinga) +5.83%
08:00AM	Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK (Newsfile)
Sep-09-22 10:23AM	Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers (Benzinga) -5.88%
07:00AM	Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors (Newsfile)
Aug-25-22 08:00AM	Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials (Newsfile)
Aug-10-22 06:27AM	Analysts Have Just Cut Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Revenue Estimates By 25% (Simply Wall St.)
Aug-04-22 07:30AM	Adaptimmune Reports Second-Quarter Financial Results and Business Update (Newsfile) +19.59%
Aug-01-22 06:21AM	Shareholders in Adaptimmune Therapeutics (NASDAQ:ADAP) are in the red if they invested five years ago (Simply Wall St.) -5.95%
Jul-21-22 08:00AM	Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022 (Newsfile)
Jul-01-22 04:45PM	Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket (Motley Fool)
11:10AM	What Kind Of Investors Own Most Of Adaptimmune Therapeutics plc (NASDAQ:ADAP)? (Simply Wall St.)
Jun-27-22 03:27PM	Why Adaptimmune Therapeutics Stock Is Popping Today (Motley Fool)
Jun-01-22 10:17AM	We're Not Worried About Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn (Simply Wall St.)
May-26-22 05:00PM	Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track (Newsfile)
May-17-22 05:03PM	Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday (Motley Fool) +10.56%
May-16-22 05:00PM	Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT (GlobeNewswire)

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '24	Sale	0.67	30,080	20,244	44,848	Jan 17 05:31 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '24	Sale	0.67	18,908	12,725	7,785	Jan 17 05:30 PM
Norry Elliot	Chief Medical Officer	Jan 17 '24	Sale	0.67	18,276	12,300	7,785	Jan 17 05:31 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '24	Sale	0.67	18,114	12,191	7,785	Jan 17 05:30 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 16 '24	Sale	0.79	9,304	7,350	14,104	Jan 17 05:31 PM
Lunger John	Chief Patient Supply Officer	Jan 16 '24	Sale	0.79	4,681	3,698	7,023	Jan 17 05:30 PM
Bertrand William C JR	Chief Operating Officer	Jan 16 '24	Sale	0.79	4,681	3,698	7,023	Jan 17 05:30 PM
Norry Elliot	Chief Medical Officer	Jan 16 '24	Sale	0.79	2,287	1,807	3,363	Jan 17 05:31 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 12 '24	Sale	0.85	17,257	14,739	26,388	Jan 12 05:00 PM
Norry Elliot	Chief Medical Officer	Jan 12 '24	Sale	0.85	7,799	6,661	11,841	Jan 12 05:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 12 '24	Sale	0.85	5,220	4,458	7,874	Jan 12 05:00 PM
Lunger John	Chief Patient Supply Officer	Jan 12 '24	Sale	0.85	5,220	4,458	7,874	Jan 12 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 11 '24	Sale	0.84	11,945	9,994	18,395	Jan 12 05:00 PM
Lunger John	Chief Patient Supply Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Norry Elliot	Chief Medical Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Sep 01 '23	Sale	0.78	2,403	1,874	3,449	Sep 01 07:00 PM
Lunger John	Chief Patient Supply Officer	Aug 01 '23	Sale	0.91	3,096	2,804	4,718	Aug 01 05:00 PM
Menzel Garry E	Director	Jul 10 '23	Sale	0.91	47,702	43,447	75,056	Jul 10 05:01 PM
Rawcliffe Adrian	Chief Executive Officer	Jun 27 '23	Sale	0.92	2,333	2,146	3,519	Jun 27 09:15 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ALLO

Allogene Therapeutics Inc

ADAP

Adaptimmune Therapeutics Plc ADR

Upgrade your FINVIZ experience